BioHarvest Sciences Inc. Common Stock

BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.

BioHarvest Sciences Inc. Common Stock trades as BHST on NASDAQ. The company is classified in Basic Materials / Agricultural Inputs and reports in USD.

The current profile places the business in Agricultural Inputs. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $34.51M of revenue and -$11.13M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

BioHarvest Sciences Inc. Common Stock can be compared against peers such as Ascent Industries Co., American Vanguard Corporation, Bioceres Crop Solutions Corp., Core Molding Technologies, Inc., FutureFuel Corp., Friedman Industries, Incorporated.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $55.28M, beta of 1.37, and return on equity of -43.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

BHST currently shows total debt of $14.10M and beta of 1.37. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 6-K (2026-05-28 00:00:00), 6-K (2026-05-14 00:00:00), 6-K (2026-05-14 00:00:00), 6-K (2026-05-14 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.bioharvest.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.